| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 23.5 | 6.3 | 5.4 |
| Other income | 0.5 | 0.9 | 1.1 |
| Total income | 24.1 | 7.3 | 6.5 |
| Profit before exceptional items & tax | 18.2 | 0.4 | 1.4 |
| Profit before tax | 18.2 | 0.4 | 1.4 |
| Net profit | 13.0 | -1.7 | 1.0 |
| Operating margin | 75.5% | 5.5% | 21.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1200.00% |
|---|---|
| Revenue, year on year | +335.20% |
| Operating profit, year on year | +5800.00% |
| Operating profit, quarter on quarter | +3640.00% |
BSE results filing, NSE: RELISH. Figures extracted from the filing.
Shukra Pharmaceuticals Ltd: key numbers
- Share price
- ₹55.87
- Market cap
- ₹2,456 Cr
- Revenue (annual)
- ₹56.73 Cr
- Net profit (annual)
- ₹22.06 Cr
- P/E (TTM)
- 72.3×Sector 50.4×
- Promoter holding
- 51.15%+0.19% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shukra Pharmaceuticals Ltd
All →Shukra Pharmaceuticals Annual General Meeting
Shukra Pharmaceuticals Ltd issued a corrigendum to its Postal Ballot notice regarding the proposed alteration of its Main Object Clause and name change.
Shukra Pharmaceuticals Annual Report
Shukra Pharmaceuticals Ltd has filed its 32nd Annual Report for the financial year 2025-26 as mandated by SEBI (LODR) regulations. The document covers the company's annual activities.
Shukra Pharmaceuticals Annual General Meeting
Shukra Pharmaceuticals has scheduled its 33rd Annual General Meeting on September 28, 2026, to be held via Video Conferencing.
Shukra Pharmaceuticals Dividend
Shukra Pharmaceuticals Ltd has fixed September 21, 2026, as the record date for a final dividend of ₹0.01 per share. Payment is subject to shareholder approval.
Shukra Pharmaceuticals Capital Structure Change
Shukra Pharmaceuticals allotted 11,73,000 equity shares following the conversion of warrants, generating Rs.3.13 Crore in exercise proceeds. This allotment increases the company's paid-up equity capital.
- Value
- ₹3.13 Cr
Shukra Pharmaceuticals Q4 FY26 Results: Net Loss of ₹1.7 Cr
Shukra Pharmaceuticals Ltd reported revenue from operations of ₹6.3 Cr (-52.6% YoY) and a net loss of ₹1.7 Cr for Q4 FY26.
- Key figure
- Net loss ₹1.7 Cr